The emerging field of osteoimmunology

Immunologic Research

Volumn 45, Issue 2-3, 2009, Pages 100-113

  Mensah, Kofi A ^a   Li, Jie ^a   Schwarz, Edward M ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

Arthritis; Osteoimmunology; Osteoporosis; Osteoprotegerin (OPG); RANK ligand; Receptor activator of nuclear factor kappa B (RANK)

Indexed keywords

ABATACEPT; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ADALIMUMAB; BONE MORPHOGENETIC PROTEIN; CHEMOKINE; CYTOKINE; ETANERCEPT; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; INTERLEUKIN 17; INTERLEUKIN 17 RECEPTOR; INTERLEUKIN 21; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; METHOTREXATE; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; PARATHYROID HORMONE; PROSTAGLANDIN E2; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; RITUXIMAB; STROMAL CELL DERIVED FACTOR 1; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNINDEXED DRUG;

ADAPTIVE IMMUNITY; ARTHRITIS; B CELL LYMPHOMA; B LYMPHOCYTE; BIOLOGICAL THERAPY; BONE; BONE REMODELING; CD4+ T LYMPHOCYTE; CELL STRUCTURE; CYTOKINE PRODUCTION; DENDRITIC CELL; EFFECTOR CELL; HEMATOPOIETIC SYSTEM; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOLOGY; INNATE IMMUNITY; JOINT CAVITY; MACROPHAGE; MAJOR HISTOCOMPATIBILITY COMPLEX; MESENCHYMAL STEM CELL; MICROENVIRONMENT; MONOCYTE; ONTOGENY; OSSIFICATION; OSTEOBLAST; OSTEOIMMUNOLOGY; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SKELETON; T LYMPHOCYTE ACTIVATION; TH17 CELL;

ALLERGY AND IMMUNOLOGY; BONE AND BONES; BONE REMODELING; HUMANS; IMMUNE SYSTEM; IMMUNOLOGIC FACTORS; OSTEOBLASTS; OSTEOGENESIS; SIGNAL TRANSDUCTION;

EID: 72449182804     PISSN: 0257277X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12026-009-8093-x     Document Type: Review

References (82)

1. SL Teitelbaum 2007 Osteoclasts: what do they do and how do they do it? Am J Pathol 170 427 35 10.2353/ajpath.2007.060834 17255310 (Pubitemid 47339379)
2. GA Rodan TJ Martin 2000 Therapeutic approaches to bone diseases Science 289 1508 14 10.1126/science.289.5484.1508 10968781 (Pubitemid 30677465)
3. WJ Boyle WS Simonet 2003 Lacey DL: osteoclast differentiation and activation Nature 423 337 42 10.1038/nature01658 12748652 (Pubitemid 40852708)
4. RJ Lories I Derese FP Luyten 2005 Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis J Clin Invest 115 1571 9 10.1172/JCI23738 15902307 (Pubitemid 40814665)
5. J Lorenzo Y Choi 2005 Osteoimmunology Immunol Rev 208 5 6 10.1111/j.0105-2896.2005.00340.x 16313336
6. MC Walsh N Kim Y Kadono J Rho SY Lee J Lorenzo Y Choi 2006 Osteoimmunology: interplay between the immune system and bone metabolism Annu Rev Immunol 24 33 63 10.1146/annurev.immunol.24.021605.090646 16551243
7. H Takayanagi 2007 Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems Nat Rev Immunol 7 292 304 10.1038/nri2062 17380158 (Pubitemid 46480961)
8. J Rho M Takami Y Choi 2004 Osteoimmunology: interactions of the immune and skeletal systems Mol Cells 17 1 9 15055519
9. A Yamaguchi T Komori T Suda 2000 Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1 Endocr Rev 21 393 411 10.1210/er.21.4.393 10950158 (Pubitemid 32275586)
10. LM Calvi GB Adams KW Weibrecht JM Weber DP Olson MC Knight RP Martin E Schipani P Divieti FR Bringhurst LA Milner HM Kronenberg DT Scadden 2003 Osteoblastic cells regulate the haematopoietic stem cell niche Nature 425 841 6 10.1038/nature02040 14574413 (Pubitemid 37351468)
11. LM Calvi NA Sims JL Hunzelman MC Knight A Giovannetti JM Saxton HM Kronenberg R Baron E Schipani 2001 Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone J Clin Invest 107 277 86 10.1172/JCI11296 11160151
12. RM Neer CD Arnaud JR Zanchetta R Prince GA Gaich JY Reginster AB Hodsman EF Eriksen S Ish-Shalom HK Genant O Wang BH Mitlak 2001 Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis N Engl J Med 344 1434 41 10.1056/NEJM200105103441904 11346808 (Pubitemid 32402100)
13. T Miyamoto O Ohneda F Arai K Iwamoto S Okada K Takagi DM Anderson T Suda 2001 Bifurcation of osteoclasts and dendritic cells from common progenitors Blood 98 2544 54 10.1182/blood.V98.8.2544 11588053
14. P Li EM Schwarz RJ O'Keefe L Ma RJ Looney CT Ritchlin BF Boyce L Xing 2004 Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11b high osteoclast precursors in tumor necrosis factor alpha-transgenic mice Arthritis Rheum 50 265 76 10.1002/art.11419 14730625 (Pubitemid 38084312)
15. CT Ritchlin SA Haas-Smith P Li DG Hicks EM Schwarz 2003 Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis J Clin Invest 111 821 31 12639988
16. D Strauss-Ayali SM Conrad DM Mosser 2007 Monocyte subpopulations and their differentiation patterns during infection J Leukoc Biol 82 244 52 10.1189/jlb.0307191 17475785 (Pubitemid 47230633)
17. S Gordon PR Taylor 2005 Monocyte and macrophage heterogeneity Nat Rev Immunol 5 953 64 10.1038/nri1733 16322748 (Pubitemid 41746764)
18. N Kawanaka M Yamamura T Aita Y Morita A Okamoto M Kawashima M Iwahashi A Ueno Y Ohmoto H Makino 2002 CD14+, CD16+ blood monocytes and joint inflammation in rheumatoid arthritis Arthritis Rheum 46 2578 86 10.1002/art.10545 12384915 (Pubitemid 36118920)
19. S Wijngaarden JA van Roon JW Bijlsma JG van de Winkel FP Lafeber 2003 Fcgamma receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti-rheumatic drugs Rheumatology (Oxford) 42 681 8 10.1093/rheumatology/keg174 (Pubitemid 37220879)
20. L Ziegler-Heitbrock 2007 The CD14+ CD16+ blood monocytes: their role in infection and inflammation J Leukoc Biol 81 584 92 10.1189/jlb.0806510 17135573 (Pubitemid 46393535)
21. F Arai T Miyamoto O Ohneda T Inada T Sudo K Brasel T Miyata DM Anderson T Suda 1999 Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-fms and receptor activator of nuclear factor {kappa}B (RANK) receptors J Exp Med 190 1741 54 10.1084/jem.190.12.1741 10601350 (Pubitemid 30013841)
22. HH Kim DE Lee JN Shin YS Lee YM Jeon CH Chung J Ni BS Kwon ZH Lee 1999 Receptor activator of NF-kappaB recruits multiple TRAF family adaptors and activates c-jun N-terminal kinase FEBS Lett 443 297 302 10.1016/S0014-5793(98) 01731-1 10025951 (Pubitemid 29080814)
23. AP Armstrong ME Tometsko M Glaccum CL Sutherland D Cosman WC Dougall 2002 A RANK/TRAF6-dependent signal transduction pathway is essential for osteoclast cytoskeletal organization and resorptive function J Biol Chem 277 44347 56 10.1074/jbc.M202009200 12185073 (Pubitemid 36157870)
24. A Naito H Yoshida E Nishioka M Satoh S Azuma T Yamamoto S Nishikawa J Inoue 2002 TRAF6-deficient mice display hypohidrotic ectodermal dysplasia Proc Natl Acad Sci USA 99 8766 71 12060722
25. MA Lomaga WC Yeh I Sarosi GS Duncan C Furlonger A Ho S Morony C Capparelli G Van S Kaufman A van der Heiden A Itie A Wakeham W Khoo T Sasaki Z Cao JM Penninger CJ Paige DL Lacey CR Dunstan WJ Boyle DV Goeddel TW Mak 1999 TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling Genes Dev 13 1015 24 10.1101/gad.13.8.1015 10215628
26. N Kobayashi Y Kadono A Naito K Matsumoto T Yamamoto S Tanaka J Inoue 2001 Segregation of TRAF6-mediated signaling pathways clarifies its role in osteoclastogenesis EMBO J 20 1271 80 10.1093/emboj/20.6.1271 11250893 (Pubitemid 32233967)
27. H Ye JR Arron B Lamothe M Cirilli T Kobayashi NK Shevde D Segal OK Dzivenu M Vologodskaia M Yim K Du S Singh JW Pike BG Darnay Y Choi H Wu 2002 Distinct molecular mechanism for initiating TRAF6 signalling Nature 418 443 7 10.1038/nature00888 12140561 (Pubitemid 34826847)
28. BR Wong D Besser N Kim JR Arron M Vologodskaia H Hanafusa Y Choi 1999 TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-src Mol Cell 4 1041 9 10.1016/S1097-2765(00)80232-4 10635328
29. BR Wong R Josien SY Lee B Sauter HL Li RM Steinman Y Choi 1997 TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor J Exp Med 186 2075 80 10.1084/jem.186.12.2075 9396779 (Pubitemid 28013694)
30. DM Anderson E Maraskovsky WL Billingsley WC Dougall ME Tometsko ER Roux MC Teepe RF DuBose D Cosman L Galibert 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 390 175 9 10.1038/36593 9367155 (Pubitemid 27507987)
31. WS Simonet DL Lacey CR Dunstan M Kelley MS Chang R Luthy HQ Nguyen S Wooden L Bennett T Boone G Shimamoto M DeRose R Elliott A Colombero HL Tan G Trail J Sullivan E Davy N Bucay L Renshaw-Gegg TM Hughes D Hill W Pattison P Campbell S Sander G Van J Tarpley P Derby R Lee WJ Boyle 1997 Osteoprotegerin: a novel secreted protein involved in the regulation of bone density Cell 89 309 19 10.1016/S0092-8674(00)80209-3 9108485
32. DL Lacey E Timms HL Tan MJ Kelley CR Dunstan T Burgess R Elliott A Colombero G Elliott S Scully H Hsu J Sullivan N Hawkins E Davy C Capparelli A Eli YX Qian S Kaufman I Sarosi V Shalhoub G Senaldi J Guo J Delaney WJ Boyle 1998 Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation Cell 93 165 76 10.1016/S0092-8674(00)81569-X 9568710 (Pubitemid 28180851)
33. H Yasuda N Shima N Nakagawa K Yamaguchi M Kinosaki S Mochizuki A Tomoyasu K Yano M Goto A Murakami E Tsuda T Morinaga K Higashio N Udagawa N Takahashi T Suda 1998 Osteoclast differentiation factor is a ligand for osteoprotegerin/ osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL Proc Natl Acad Sci USA 95 3597 602 10.1073/pnas.95.7.3597 9520411 (Pubitemid 28173173)
34. S Takeshita K Kaji A Kudo 2000 Identification and characterization of the new osteoclast progenitor with macrophage phenotypes being able to differentiate into mature osteoclasts J Bone Miner Res 15 1477 88 10.1359/jbmr.2000.15.8.1477 10934646
35. EH Chen E Grote W Mohler A Vignery 2007 Cell-cell fusion FEBS Lett 581 2181 93 10.1016/j.febslet.2007.03.033 17395182 (Pubitemid 46722606)
36. H Staege A Brauchlin G Schoedon A Schaffner 2001 Two novel genes FIND and LIND differentially expressed in deactivated and listeria-infected human macrophages Immunogenetics 53 105 13 10.1007/s002510100306 11345586 (Pubitemid 32289625)
37. FC Hartgers JL Vissers MW Looman C van Zoelen C Huffine CG Figdor GJ Adema 2000 DC-STAMP, a novel multimembrane-spanning molecule preferentially expressed by dendritic cells Eur J Immunol 30 3585 90 10.1002/1521-4141(200012) 30:12<3585::AID-IMMU3585>3.0.CO;2-Y 11169400 (Pubitemid 32005231)
38. M Yagi T Miyamoto Y Sawatani K Iwamoto N Hosogane N Fujita K Morita K Ninomiya T Suzuki K Miyamoto Y Oike M Takeya Y Toyama T Suda 2005 DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells J Exp Med 202 345 51 10.1084/jem.20050645 16061724 (Pubitemid 41126951)
39. M Yagi T Miyamoto Y Toyama T Suda 2006 Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells J Bone Miner Metab 24 355 8 10.1007/s00774-006-0697-9 16937266 (Pubitemid 44306170)
40. A Vignery 2005 Macrophage fusion: the making of osteoclasts and giant cells J Exp Med 202 337 40 10.1084/jem.20051123 16061722 (Pubitemid 41126949)
41. Y Sawatani T Miyamoto S Nagai M Maruya J Imai K Miyamoto N Fujita K Ninomiya T Suzuki R Iwasaki Y Toyama M Shinohara S Koyasu T Suda 2008 The role of DC-STAMP in maintenance of immune tolerance through regulation of dendritic cell function Int Immunol 20 1259 68 10.1093/intimm/dxn082 18653699
42. T Kukita N Wada A Kukita T Kakimoto F Sandra K Toh K Nagata T Iijima M Horiuchi H Matsusaki K Hieshima O Yoshie H Nomiyama 2004 RANKL-induced DC-STAMP is essential for osteoclastogenesis J Exp Med 200 941 6 10.1084/jem.20040518 15452179 (Pubitemid 39362930)
43. T Miyamoto 2006 The dendritic cell-specific transmembrane protein DC-STAMP is essential for osteoclast fusion and osteoclast bone-resorbing activity Mod Rheumatol 16 341 2 10.1007/s10165-006-0524-0 17164993 (Pubitemid 44921579)
44. DH Jones YY Kong JM Penninger 2002 Role of RANKL and RANK in bone loss and arthritis Ann Rheum Dis 61 Suppl 2 ii32 9 12379618
45. JL Moreno M Kaczmarek AD Keegan M Tondravi 2003 IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL Blood 102 1078 86 10.1182/blood-2002-11-3437 12689929 (Pubitemid 36917809)
46. A Rivollier M Mazzorana J Tebib M Piperno T Aitsiselmi C Rabourdin-Combe P Jurdic C Servet-Delprat 2004 Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment Blood 104 4029 37 10.1182/blood-2004-01-0041 15308576 (Pubitemid 39620153)
47. P Li EM Schwarz 2003 The TNF-alpha transgenic mouse model of inflammatory arthritis Springer Semin Immunopathol 25 19 33 10.1007/s00281-003-0125-3 12904889 (Pubitemid 37000036)
48. Y Abu-Amer FP Ross KP McHugh A Livolsi JF Peyron SL Teitelbaum 1998 Tumor necrosis factor-alpha activation of nuclear transcription factor-kappaB in marrow macrophages is mediated by c-src tyrosine phosphorylation of ikappa balpha J Biol Chem 273 29417 23 10.1074/jbc.273.45.29417 9792645 (Pubitemid 28509944)
49. J Keffer L Probert H Cazlaris S Georgopoulos E Kaslaris D Kioussis G Kollias 1991 Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis EMBO J 10 4025 31 1721867
50. D Diarra M Stolina K Polzer J Zwerina MS Ominsky D Dwyer A Korb J Smolen M Hoffmann C Scheinecker D van der Heide R Landewe D Lacey WG Richards G Schett 2007 Dickkopf-1 is a master regulator of joint remodeling Nat Med 13 156 63 10.1038/nm1538 17237793 (Pubitemid 46245765)
51. BR Wong R Josien Y Choi 1999 TRANCE is a TNF family member that regulates dendritic cell and osteoclast function J Leukoc Biol 65 715 24 10380891
52. YY Kong U Feige I Sarosi B Bolon A Tafuri S Morony C Capparelli J Li R Elliott S McCabe T Wong G Campagnuolo E Moran ER Bogoch G Van LT Nguyen PS Ohashi DL Lacey E Fish WJ Boyle JM Penninger 1999 Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand Nature 402 304 9 10.1038/46303 10580503
53. Y Abu-Amer 2001 IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB J Clin Invest 107 1375 85 10.1172/JCI10530 11390419
54. D Plows G Kontogeorgos G Kollias 1999 Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen J Immunol 162 1018 23 9916728
55. LE Harrington RD Hatton PR Mangan H Turner TL Murphy KM Murphy CT Weaver 2005 Interleukin 17-producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages Nat Immunol 6 1123 32 10.1038/ni1254 16200070 (Pubitemid 41541790)
56. C Dong 2008 TH17 cells in development: an updated view of their molecular identity and genetic programming Nat Rev Immunol 8 337 48 10.1038/nri2295 18408735 (Pubitemid 351595217)
57. N Manel D Unutmaz DR Littman 2008 The differentiation of human T(H)-17 cells requires transforming growth factor-beta and induction of the nuclear receptor RORgammat Nat Immunol 9 641 9 10.1038/ni.1610 18454151 (Pubitemid 351714729)
58. W Ouyang JK Kolls Y Zheng 2008 The biological functions of T helper 17 cell effector cytokines in inflammation Immunity 28 454 67 10.1016/j.immuni. 2008.03.004 18400188
59. A Paradowska W Masliniski A Grzybowska-Kowalczyk J Lacki 2007 The function of interleukin 17 in the pathogenesis of rheumatoid arthritis Arch Immunol Ther Exp (Warsz) 55 329 34 10.1007/s00005-007-0032-8
60. E Lubberts 2003 The role of IL-17 and family members in the pathogenesis of arthritis Curr Opin Investig Drugs 4 572 7 12833651
61. KA Bush KM Farmer JS Walker BW Kirkham 2002 Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 fc fusion protein Arthritis Rheum 46 802 5 10.1002/art.10173 11920418 (Pubitemid 34214263)
62. E Lubberts MI Koenders B Oppers-Walgreen L van den Bersselaar CJ Coenen-de Roo LA Joosten WB van den Berg 2004 Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of collagen-induced arthritis reduces joint inflammation, cartilage destruction, and bone erosion Arthritis Rheum 50 650 9 10.1002/art.20001 14872510 (Pubitemid 38198849)
63. M Chabaud JM Durand N Buchs F Fossiez G Page L Frappart P Miossec 1999 Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium Arthritis Rheum 42 963 70 10.1002/1529-0131(199905)42: 5<963::AID-ANR15>3.0.CO;2-E 10323452 (Pubitemid 29215007)
64. S Kotake N Udagawa N Takahashi K Matsuzaki K Itoh S Ishiyama S Saito K Inoue N Kamatani MT Gillespie TJ Martin T Suda 1999 IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis J Clin Invest 103 1345 52 10.1172/JCI5703 10225978
65. S Shahrara Q Huang AM Mandelin II RM Pope 2008 TH-17 cells in rheumatoid arthritis Arthritis Res Ther 10 R93 10.1186/ar2477 18710567
66. G Steiner J Smolen 2002 Autoantibodies in rheumatoid arthritis and their clinical significance Arthritis Res 4 Suppl 2 S1 5 10.1186/ar551 12110150
67. R Matthews 2007 Autoimmune diseases: the B cell slayer Science 318 1232 3 10.1126/science.318.5854.1232 18033858 (Pubitemid 350172866)
68. S Takemura A Braun C Crowson PJ Kurtin RH Cofield WM O'Fallon JJ Goronzy CM Weyand 2001 Lymphoid neogenesis in rheumatoid synovitis J Immunol 167 1072 80 11441118
69. S Takemura PA Klimiuk A Braun JJ Goronzy CM Weyand 2001 T cell activation in rheumatoid synovium is B cell dependent J Immunol 167 4710 8 11591802
70. ME Duddy A Alter A Bar-Or 2004 Distinct profiles of human B cell effector cytokines: a role in immune regulation? J Immunol 172 3422 7 15004141
71. Y Li G Toraldo A Li X Yang H Zhang WP Qian MN Weitzmann 2007 B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo Blood 109 3839 48 10.1182/blood-2006-07-037994 17202317 (Pubitemid 46641735)
72. B Gortz S Hayer K Redlich J Zwerina M Tohidast-Akrad B Tuerk C Hartmann G Kollias G Steiner JS Smolen G Schett 2004 Arthritis induces lymphocytic bone marrow inflammation and endosteal bone formation J Bone Miner Res 19 990 8 10.1359/JBMR.040205 15125796 (Pubitemid 41103456)
73. P Mease 2006 Psoriatic arthritis update Bull NYU Hosp Jt Dis 64 25 31 17121486
74. D van der Heijde A Kavanaugh DD Gladman C Antoni GG Krueger C Guzzo B Zhou LT Dooley K de Vlam P Geusens C Birbara D Halter A Beutler 2007 Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2 Arthritis Rheum 56 2698 707 10.1002/art.22805 17665424 (Pubitemid 47237288)
75. PJ Mease DD Gladman CT Ritchlin EM Ruderman SD Steinfeld EH Choy JT Sharp PA Ory RJ Perdok MA Weinberg Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group 2005 Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial Arthritis Rheum 52 3279 89 10.1002/art.21306 16200601 (Pubitemid 41447111)
76. JCW Edwards L Szeczepanski J Szechinski 2002 Efficacy and safety of rituximab, a B cell targeted chimeric antibody: a randomized placebo-controlled trial in rheumatoid arthritis [abstract] Arthritis Rheum 46 S446 10.1002/art.10507 (Pubitemid 35315911)
77. SB Cohen P Emery MW Greenwald M Dougados RA Furie MC Genovese EC Keystone JE Loveless GR Burmester MW Cravets EW Hessey T Shaw MC Totoritis REFLEX Trial Group 2006 Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks Arthritis Rheum 54 2793 806 10.1002/art.22025 16947627 (Pubitemid 44497758)
78. AM Manadan JA Block 2008 Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade Am J Ther 15 53 8 10.1097/MJT.0b013e31814daf9b 18223354 (Pubitemid 351161182)
79. R Axmann S Herman M Zaiss S Franz K Polzer J Zwerina M Herrmann J Smolen G Schett 2008 CTLA-4 directly inhibits osteoclast formation Ann Rheum Dis 67 1603 9 10.1136/ard.2007.080713 18203760
80. EM Schwarz CT Ritchlin 2007 Clinical development of anti-RANKL therapy Arthritis Res Ther 9 Suppl 1 S7 10.1186/ar2171 17634146 (Pubitemid 351803969)
81. PJ Bekker D Holloway A Nakanishi M Arrighi PT Leese CR Dunstan 2001 The effect of a single dose of osteoprotegerin in postmenopausal women J Bone Miner Res 16 348 60 10.1359/jbmr.2001.16.2.348 11204435
82. MR McClung EM Lewiecki SB Cohen MA Bolognese GC Woodson AH Moffett M Peacock PD Miller SN Lederman CH Chesnut D Lain AJ Kivitz DL Holloway C Zhang MC Peterson PJ Bekker AMG 162 Bone Loss Study Group 2006 Denosumab in postmenopausal women with low bone mineral density N Engl J Med 354 821 31 10.1056/NEJMoa044459 16495394 (Pubitemid 43290920)